{"url_path":"/sec/mcrb/8-k/2026-07-08/item-3","section_key":"item-3","section_title":"Item 3 Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-07-08","source_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","accession_number":"0001193125-26-298525","cik":"0001609809","ticker":"MCRB","issuer_name":"Seres Therapeutics, Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1609809/0001193125-26-298525-index.html","primary_entity_key":"0001609809","primary_entity_name":"Seres Therapeutics, Inc."},"word_count":30,"has_tables":true,"body_markdown":"Item 3 - Approval, on an advisory (non-binding) basis, of the compensation of the Company’s named executive officers.\n\n \n\nVotes FOR\n  \nVotes AGAINST\n  \nVotes ABSTAINED\n  \nBroker Non-Votes\n\n3,374,813\n  \n620,353\n  \n121,295\n  \n868,715"}